Kala Pharmaceuticals (KALA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

KALA Stock Forecast

Kala Pharmaceuticals stock forecast is as follows: an average price target of $15.00 (represents a 121.89% upside from KALA’s last price of $6.76) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

KALA Price Target

The average price target for Kala Pharmaceuticals (KALA) is $15.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 121.89% upside from KALA's last price of $6.76.

KALA Analyst Ratings

Buy

According to 5 Wall Street analysts, Kala Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KALA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Kala Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 07, 2024	Yi Chen	H.C. Wainwright	$15.00	$6.19	142.33%	121.89%
May 17, 2024	Yi Chen	H.C. Wainwright	$18.00	$6.50	176.92%	166.27%
Apr 03, 2024	Yi Chen	H.C. Wainwright	$21.00	$7.99	162.83%	210.65%

Row per page

Go to

The latest Kala Pharmaceuticals stock forecast, released on Aug 07, 2024 by Yi Chen from H.C. Wainwright, set a price target of $15.00, which represents a 142.33% increase from the stock price at the time of the forecast ($6.19), and a 121.89% increase from KALA last price ($6.76).

Kala Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	3
Avg Price Target	-	-	$18.00
Last Closing Price	$6.76	$6.76	$6.76
Upside/Downside	-100.00%	-100.00%	166.27%

In the current month, the average price target of Kala Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kala Pharmaceuticals's last price of $6.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 19, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 07, 2024	H.C. Wainwright	Buy	Buy	Hold
May 17, 2024	H.C. Wainwright	Buy	Buy	Hold
Apr 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Dec 29, 2022	Wedbush	Outperform	Outperform	Hold
Aug 15, 2022	Piper Sandler	Buy	Buy	Hold
Apr 25, 2022	Zacks Investment Research	-	Hold	Upgrade

Row per page

Go to

Kala Pharmaceuticals's last stock rating was published by Oppenheimer on Aug 19, 2024. The company gave KALA a "Outperform" rating, the same as its previous rate.

Kala Pharmaceuticals Financial Forecast

Kala Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	$1.23M	$420.00K	$2.10M	$1.37M	$1.86M	$3.07M	$3.05M	$3.27M	$2.24M	$2.22M	$833.00K	$1.07M	$1.18M	$1.45M	$2.06M	$1.39M
Avg Forecast	-	-	-	-	-	-	-	$2.50M	$1.30M	$1.98M	$62.50M	$2.02M	$3.11M	$3.38M	$4.97M	$5.25M	$3.72M	$2.39M	$2.01M	$733.21K	$3.06M	$2.91M	$3.56M	$2.69M	$1.10M
High Forecast	-	-	-	-	-	-	-	$2.50M	$1.56M	$2.38M	$62.50M	$2.02M	$3.11M	$3.38M	$4.97M	$5.25M	$3.72M	$2.39M	$2.01M	$733.21K	$3.06M	$2.91M	$3.56M	$2.69M	$1.10M
Low Forecast	-	-	-	-	-	-	-	$2.50M	$1.04M	$1.58M	$62.50M	$2.02M	$3.11M	$3.38M	$4.97M	$5.25M	$3.72M	$2.39M	$2.01M	$733.21K	$3.06M	$2.91M	$3.56M	$2.69M	$1.10M
# Analysts	-	-	-	-	-	-	-	7	14	14	6	8	6	7	11	7	13	13	7	7	9	8	6	10	6
Surprise %	-	-	-	-	-	-	-	-	-	0.62%	0.01%	1.04%	0.44%	0.55%	0.62%	0.58%	0.88%	0.94%	1.11%	1.14%	0.35%	0.41%	0.41%	0.76%	1.26%

Kala Pharmaceuticals's average Quarter revenue forecast for Mar 23 based on 14 analysts is $1.30M, with a low forecast of $1.04M, and a high forecast of $1.56M. KALA's average Quarter revenue forecast represents a 6.00% increase compared to the company's last Quarter revenue of $1.23M (Dec 22).

Kala Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	-	-	-	-	-	-	-	7	14	14	6	8	6	7	11	7	13	13	7	7	9	8	6	10	6
EBITDA	-	-	-	-	-	-	-	$-8.76M	$-11.36M	$-10.17M	$-13.70M	$-26.60M	$-30.69M	$-45.28M	$-25.80M	$-34.15M	$-28.02M	$-28.70M	$-25.57M	$-20.95M	$-19.60M	$-19.58M	$-20.77M	$-21.98M	$-22.69M
Avg Forecast	-	-	-	-	-	-	-	$-1.50M	$-29.17M	$-25.40M	$-37.50M	$-1.21M	$-23.06M	$-2.03M	$-2.98M	$-3.15M	$-35.85M	$-1.43M	$-1.21M	$-439.93K	$-18.44M	$-1.74M	$-2.13M	$-1.61M	$-22.69M
High Forecast	-	-	-	-	-	-	-	$-1.50M	$-23.34M	$-20.32M	$-37.50M	$-1.21M	$-18.45M	$-2.03M	$-2.98M	$-3.15M	$-28.68M	$-1.43M	$-1.21M	$-439.93K	$-14.76M	$-1.74M	$-2.13M	$-1.61M	$-18.15M
Low Forecast	-	-	-	-	-	-	-	$-1.50M	$-35.01M	$-30.48M	$-37.50M	$-1.21M	$-27.67M	$-2.03M	$-2.98M	$-3.15M	$-43.02M	$-1.43M	$-1.21M	$-439.93K	$-22.13M	$-1.74M	$-2.13M	$-1.61M	$-27.22M
Surprise %	-	-	-	-	-	-	-	5.84%	0.39%	0.40%	0.37%	21.97%	1.33%	22.33%	8.66%	10.84%	0.78%	20.05%	21.22%	47.63%	1.06%	11.23%	9.74%	13.61%	1.00%

undefined analysts predict KALA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kala Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Kala Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	-	-	-	-	-	-	-	7	14	14	6	8	6	7	11	7	13	13	7	7	9	8	6	10	6
Net Income	-	-	-	-	-	-	-	$-8.70M	$-18.70M	$-13.86M	$73.45M	$-27.26M	$-33.00M	$-49.64M	$-28.13M	$-36.50M	$-30.41M	$-31.11M	$-27.95M	$-23.31M	$-21.95M	$-21.96M	$-23.18M	$-23.82M	$-25.39M
Avg Forecast	$-6.66M	$-5.97M	$-6.02M	$-11.89M	$-11.43M	$-11.25M	$-13.35M	$-13.79M	$-31.25M	$-27.53M	$32.57M	$-65.91M	$-24.71M	$-59.57M	$-71.21M	$-65.16M	$-38.91M	$-73.09M	$-65.60M	$-63.08M	$-20.66M	$-91.29M	$-96.97M	$-110.83M	$-25.39M
High Forecast	$-6.66M	$-5.97M	$-6.02M	$-11.89M	$-9.71M	$-11.25M	$-13.35M	$-13.79M	$-25.00M	$-22.02M	$32.57M	$-65.91M	$-19.76M	$-59.57M	$-71.21M	$-65.16M	$-31.13M	$-73.09M	$-65.60M	$-63.08M	$-16.53M	$-91.29M	$-96.97M	$-110.83M	$-20.31M
Low Forecast	$-6.66M	$-5.97M	$-6.02M	$-11.89M	$-13.15M	$-11.25M	$-13.35M	$-13.79M	$-37.50M	$-33.03M	$32.57M	$-65.91M	$-29.65M	$-59.57M	$-71.21M	$-65.16M	$-46.69M	$-73.09M	$-65.60M	$-63.08M	$-24.80M	$-91.29M	$-96.97M	$-110.83M	$-30.47M
Surprise %	-	-	-	-	-	-	-	0.63%	0.60%	0.50%	2.25%	0.41%	1.34%	0.83%	0.39%	0.56%	0.78%	0.43%	0.43%	0.37%	1.06%	0.24%	0.24%	0.21%	1.00%

Kala Pharmaceuticals's average Quarter net income forecast for Dec 22 is $-27.53M, with a range of $-33.03M to $-22.02M. KALA's average Quarter net income forecast represents a -137.48% decrease compared to the company's last Quarter net income of $73.45M (Sep 22).

Kala Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	-	-	-	-	-	-	-	7	14	14	6	8	6	7	11	7	13	13	7	7	9	8	6	10	6
SG&A	-	-	-	-	-	-	-	$4.95M	$6.03M	$5.83M	$9.55M	$22.67M	$26.98M	$24.03M	$25.35M	$27.99M	$27.70M	$26.47M	$23.89M	$15.30M	$15.41M	$14.49M	$15.28M	$17.01M	$18.24M
Avg Forecast	-	-	-	-	-	-	-	$25.25M	$13.15M	$20.00M	$631.29M	$20.39M	$31.37M	$34.13M	$50.16M	$53.03M	$37.59M	$24.11M	$20.29M	$7.41M	$30.86M	$29.36M	$35.91M	$27.19M	$11.14M
High Forecast	-	-	-	-	-	-	-	$25.25M	$15.78M	$24.00M	$631.29M	$20.39M	$31.37M	$34.13M	$50.16M	$53.03M	$37.59M	$24.11M	$20.29M	$7.41M	$30.86M	$29.36M	$35.91M	$27.19M	$11.14M
Low Forecast	-	-	-	-	-	-	-	$25.25M	$10.52M	$16.00M	$631.29M	$20.39M	$31.37M	$34.13M	$50.16M	$53.03M	$37.59M	$24.11M	$20.29M	$7.41M	$30.86M	$29.36M	$35.91M	$27.19M	$11.14M
Surprise %	-	-	-	-	-	-	-	0.20%	0.46%	0.29%	0.02%	1.11%	0.86%	0.70%	0.51%	0.53%	0.74%	1.10%	1.18%	2.07%	0.50%	0.49%	0.43%	0.63%	1.64%

Kala Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KALA last annual SG&A of $4.95M (Sep 23).

Kala Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	-	-	-	-	-	-	-	7	14	14	6	8	6	7	11	7	13	13	7	7	9	8	6	10	6
EPS	-	-	-	-	-	-	-	$-3.41	$-9.04	$-8.60	$49.00	$-18.50	$-22.41	$-38.16	$-21.62	$-28.27	$-24.66	$-27.33	$-24.94	$-20.92	$-26.93	$-31.46	$-33.91	$-35.16	$-37.47
Avg Forecast	$-1.44	$-1.29	$-1.30	$-2.57	$-2.47	$-2.43	$-4.41	$-2.98	$-4.85	$-6.55	$10.75	$-21.75	$-16.82	$-19.66	$-23.50	$-21.50	$-23.66	$-24.12	$-21.65	$-20.82	$-25.30	$-30.13	$-32.00	$-36.57	$-37.50
High Forecast	$-1.44	$-1.29	$-1.30	$-2.57	$-2.10	$-2.43	$-4.41	$-2.98	$-4.85	$-6.55	$10.75	$-21.75	$-16.82	$-19.66	$-23.50	$-21.50	$-23.66	$-24.12	$-21.65	$-20.82	$-25.30	$-30.13	$-32.00	$-36.57	$-37.50
Low Forecast	$-1.44	$-1.29	$-1.30	$-2.57	$-2.84	$-2.43	$-4.41	$-2.98	$-4.85	$-6.55	$10.75	$-21.75	$-16.82	$-19.66	$-23.50	$-21.50	$-23.66	$-24.12	$-21.65	$-20.82	$-25.30	$-30.13	$-32.00	$-36.57	$-37.50
Surprise %	-	-	-	-	-	-	-	1.14%	1.87%	1.31%	4.56%	0.85%	1.33%	1.94%	0.92%	1.31%	1.04%	1.13%	1.15%	1.01%	1.06%	1.04%	1.06%	0.96%	1.00%

According to 14 Wall Street analysts, Kala Pharmaceuticals's projected average Quarter EPS for Dec 22 is $-6.55, with a low estimate of $-6.55 and a high estimate of $-6.55. This represents a -113.38% decrease compared to KALA previous annual EPS of $49.00 (Sep 22).

Kala Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
KALA	Kala Pharmaceuticals	$6.76	$15.00	121.89%	Buy
DVAX	Dynavax	$13.39	$24.50	82.97%	Buy
ALKS	Alkermes	$28.35	$36.38	28.32%	Hold
ORGO	Organogenesis	$4.01	$5.00	24.69%	Buy
NBIX	Neurocrine Biosciences	$122.88	$147.35	19.91%	Buy
ITCI	Intra-Cellular Therapies	$87.63	$94.50	7.84%	Buy
ALIM	Alimera Sciences	$5.54	$5.75	3.79%	Hold
DCPH	Deciphera Pharmaceuticals	$25.59	$26.32	2.85%	Hold
LFCR	Lifecore Biomedical	$6.68	$6.50	-2.69%	Buy
GHSI	Guardion Health Sciences	$3.22	$0.01	-99.69%	Buy

KALA Forecast FAQ

Is Kala Pharmaceuticals a good buy?

Yes, according to 5 Wall Street analysts, Kala Pharmaceuticals (KALA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of KALA's total ratings.

What is KALA's price target?

Kala Pharmaceuticals (KALA) average price target is $15 with a range of $15 to $15, implying a 121.89% from its last price of $6.76. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Kala Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for KALA stock, the company can go up by 121.89% (from the last price of $6.76 to the average price target of $15), up by 121.89% based on the highest stock price target, and up by 121.89% based on the lowest stock price target.

Can Kala Pharmaceuticals stock reach $10?

KALA's average twelve months analyst stock price target of $15 supports the claim that Kala Pharmaceuticals can reach $10 in the near future.

What are Kala Pharmaceuticals's analysts' financial forecasts?

Kala Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-36.023M (high $-34.306M, low $-37.74M), average SG&A $0 (high $0, low $0), and average EPS is $-9.305 (high $-8.934, low $-9.676). KALA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-30.542M (high $-30.542M, low $-30.542M), average SG&A $0 (high $0, low $0), and average EPS is $-6.6 (high $-6.6, low $-6.6).

Did the KALA's actual financial results beat the analysts' financial forecasts?

Based on Kala Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $3.89M, which missed the average analysts forecast of $69.6M by -94.41%. Apple's EBITDA was $-81.618M, missing the average prediction of $-87.17M by -6.37%. The company's net income was $-223K, missing the average estimation of $-85.565M by -99.74%. Apple's SG&A was $65.04M, missing the average forecast of $703.04M by -90.75%. Lastly, the company's EPS was $-0.15, missing the average prediction of $-34.377 by -99.56%. In terms of the last quarterly report (Dec 2022), Kala Pharmaceuticals's revenue was $1.23M, missing the average analysts' forecast of $1.98M by -37.98%. The company's EBITDA was $-10.169M, missing the average prediction of $-25.397M by -59.96%. Kala Pharmaceuticals's net income was $-13.86M, missing the average estimation of $-27.527M by -49.65%. The company's SG&A was $5.83M, missing the average forecast of $20M by -70.85%. Lastly, the company's EPS was $-8.6, beating the average prediction of $-6.555 by 31.20%